Sanjiv S. Agarwala, MDSanjiv S. Agarwala, MD
Chief, Oncology & Hematology
St. Luke’s University Health Network
Professor of Medicine
Temple University
Philadelphia, Pennsylvania

 

 

Listen to Dr. Agarwala provide answers on frequently asked questions about biosimilars:

  1. Where is the US on the “learning curve” with regard to biosimilars?
    Listen Listen

  2. How comfortable are US health care providers with the safety and efficacy data available for biosimilars?
    Listen Listen

  3. Are clinicians drawing on the European experience with biosimilars to inform understanding?
    Listen Listen

  4. What are the challenges ahead for the integration of biosimilars into clinical practice?
    Listen Listen

  5. What is the current status of states legislation related to interchangeability?
    Listen Listen

  6. What are the considerations for P&T committees regarding biosimilars?
    Listen Listen

  7. Can you comment on the importance of patient education related to biosimilars?
    Listen Listen

  8. What new developments related to biosimilars are anticipated in 2016?
    Listen Listen

Access other Therapeutic Areas:


 

New & Noteworthy